| Document |
Document Title |
|
WO/2002/043449A1 |
A luminescent element which comprises an anode, a cathode, and a luminescent substance interposed therebetween and which luminesces upon reception of electric energy, characterized by having at least one of the following compounds (a) to...
|
|
WO/2002/039879A2 |
A method for treating sexual dysfunction in a patient taking anti-depressant medication in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof to...
|
|
WO2001087308B1 |
The present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(+/-)-substituted-5,5a,6,7,8...
|
|
WO/2002/036545A1 |
The invention relates to a novel process for producing a the intermediary compound $g(a), $g(a)', dicyano-$g(b), $g(b)- pentamethyleneglutarimide. The process includes the steps of reacting a ketone such as cyclohexanone with ethylcyanoa...
|
|
WO/2002/036572A1 |
Remedies and/or preventives for extaocular inflammatory diseases or eye itch. More particularly, remedies and/or preventives for extaocular inflammatory diseases or eye itch which comprise as the active ingredient compounds represented b...
|
|
WO/2002/036568A1 |
Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are any of a number of groups as defined in the specification, A and D are as defined in the specifi...
|
|
WO/2002/034753A2 |
The present invention relates to 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein said 'A' is a 5-7 membered heterocyclic ring as defined in the specification and to pharmaceutical compositions and meth...
|
|
WO/2002/032901A2 |
A compound of the formula (I) or the pharmaceutically acceptable salt thereof; wherein a, c, d, k, l, m, W, X, Y Z, R?1¿, and R?4¿ are as defined, and useful to treat inflammation and other immune disorders.
|
|
WO/2002/030904A1 |
Compounds of formula (I): are inhibitors of the enzyme L¿p?-PLA¿2? and are of use in therapy, in particular for treating atherosclerosis.
|
|
WO/2002/030930A2 |
Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and...
|
|
WO/2002/030931A2 |
Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and...
|
|
WO2001015656A9 |
A compound having a general formula (II) wherein R1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH2)nNR'R'', (CH2)nCHOHCH2NR'R'', wherein n is an integer; RQ, RT, R', and R'' are each independently a ...
|
|
WO/2002/028837A1 |
The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R?1¿ represents C¿1-6?alkyl; cycloC¿3-12?alkyl or (cycloC¿3-12?alkyl)C¿1-6?alkyl, wherein one or more hydrogen atoms in a C¿1-6?alkyl-...
|
|
WO/2002/028830A1 |
Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof which have an effect of inhibiting $g(a)4 integrin and, therefore, are useful as remedies or preventives for inflammatory diseases wherein the $g(a)4 integri...
|
|
WO/2002/026727A2 |
Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid...
|
|
WO/2002/026714A1 |
Novel spiro compounds represented by the general formula (|) wherein A?1¿ and A?2¿ are each an optionally substituted benzene ring; E is a divalent chain hydrocarbon group which may be substituted; X is CO or the like; R?1¿ is an opti...
|
|
WO/2002/025648A1 |
The invention relates to an optical data carrier containing a preferably transparent substrate which is optionally coated with one or more reflecting layers. A light-inscribable information layer and optionally one or more reflecting lay...
|
|
WO/2002/025205A1 |
The invention relates to an optical data support which can be written once, to the use of co-phthalocyanin complexes as light-absorbing compounds in the optically writable information layer of optical data supports, especially for CD-Rs,...
|
|
WO/2002/024636A2 |
N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
|
|
WO/2002/020526A2 |
Disclosed are cyclic and acyclic amidines, pharmaceutical compositions containing such amidines, and their use in treating or preventing progesterone receptor mediated diseases or conditions, such as osteopenia and osteoporosis.
|
|
WO/2002/018361A2 |
Compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to trea...
|
|
WO/2002/018368A1 |
The present invention discloses novel tricyclic compounds represented by the formula (1.0), a prodrug thereof, or a pharmaceutically acceptable salt or solvate of the compound or of said prodrug useful for inhibiting farnesyl protein tra...
|
|
WO/2002/016325A1 |
The present invention discloses thaliporphine and its derivatives for the treatment and/or prophylaxis of cardiac diseases, including cardiac arrhytmia, myocardial ischemia or myocardial infraction, and sudden death caused by cardiac arr...
|
|
WO/2002/014279A1 |
New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysf...
|
|
WO/2002/013824A1 |
The present invention is directed to compounds of the formula I (wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿ and X are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are...
|
|
WO/2002/013827A1 |
The present invention relates to a novel process for the preparation of compounds of the fornula (IX) wherein R?1¿, R?2¿, R?4¿, R?5¿, R?6¿ and A are as defined herein, and to certain derivations of Formula (IX) which are useful for ...
|
|
WO/2002/012194A1 |
The invention relates to cancer therapy and concerns novel anticancer agents of the phenanthridine class having a very particular action mechanism. The invention also concerns novel chemical compounds and their therapeutic use in humans.
|
|
WO/2002/010135A1 |
3,4-Dihydroisoquinoline derivative compounds represented by the following general formula (I) (wherein each symbol has the meaning as specified in the description) or nontoxic salts thereof. Because of having a CB2 receptor agonist activ...
|
|
WO/2002/006239A1 |
The N-oxides of the compounds of the formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
|
|
WO/2002/006238A1 |
Compounds of the formula I, in which R1, R2, R3, R31, R4, R5, R51, R6, R7 and R20 have the meanings indicated in the description, are novel active PDE4 inhibitors.
|
|
WO/2002/006240A1 |
This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
|
|
WO/2002/005616A1 |
Compounds of the formula I, in which R6 is SO¿2?N(R7)R8, COOR9, CON(R10)R11 or a R15-substituted tetrazol-5-yl radical, R18 is hydroxyl, halogen, nitro, amino, 1-4C-alkyl or 1-4C-alkoxy, or the salts, the N-oxide and the salts of the N-...
|
|
WO/2001/096311A2 |
Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and...
|
|
WO/2001/090077A1 |
Compounds of Formula (1) wherein: one of R¿3? and R¿4? is -QP and the other of R¿3? and R¿4? is one of hydrogen, methyl, trifluoromethyl, nitro, amino, halogen and I-piperazine. Q is one of (A) and (B) and P is Z-(N(R¿5?R¿6?)), Z o...
|
|
WO/2001/087894A1 |
Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected fro...
|
|
WO/2001/087895A1 |
Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a l-labile, 10-hydroxy, ...
|
|
WO/2001/081654A1 |
Fluorescent monomers are described and claimed which are synthesized by reacting a substituted or non-substituted naphthalic anhydride with an amine and with a moiety containing a polymerizable group. Such monomers are useful for the pre...
|
|
WO/2001/079199A1 |
Acetylene derivatives represented by the general formula (I); and herbicides containing the derivatives and/or salts thereof as the active ingredient. In said formula R?1¿ to R?6¿, X?1¿, Y, Z and q are each as defined in the descripti...
|
|
WO/2001/078713A1 |
Compounds of general formula (I). wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may...
|
|
WO/2001/079175A1 |
A process is provided for preparing a compound having the formula (I) comprising: (a) reacting a compound having the formula (II) with an isocyanate having the formula R?1¿NCO to produce a compound having the formula (III); (b) optional...
|
|
WO/2001/079204A1 |
The invention relates to novel compounds of the formula (I) wherein W, X, Y, Z, G, A, B, Q?1¿, Q?2¿ and D are defined as per the description, to several methods for the production of said compounds and to their use as pesticides and he...
|
|
WO/2001/076602A1 |
Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apormorphine effectiv...
|
|
WO/2001/077115A1 |
Compounds having a fused ecteinascidin five ring system with a 1,4 bridge having the structure of formula (VIa or VIb) and compounds in which the -NH¿2? or -OH of the 1,4 bridge is derivatised are disclosed. Such compounds are useful in...
|
|
WO/2001/074358A1 |
Methods for administering apomorphine to a patient for the treatment of sexual dysfunctions while reducing undesirable side effects are disclosed. In the methods, the concentration of apomorphine is attained within the patients' plasma o...
|
|
WO/2001/072707A2 |
This invention provides caspase inhibitors of formula (I): wherein Z is oxygen or sulfur; R?1¿ is hydrogen, -CHN¿2?,R, CH¿2?OR, CH¿2?SR, or -CH¿2?Y; Y is an electronegative leaving group; R?2¿ is CO¿2?H, CH¿2?CO¿2?H, or esters, ...
|
|
WO/2001/072713A1 |
The invention provides non-steroidal estrogenic compounds with estrogenic and anti-estrogenic compounds effects for treatment of estrogen-deficiency related disorders, which compounds are having formula (I) wherein, one of R?a¿ or R?b¿...
|
|
WO/2001/070675A2 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2001/068588A1 |
An $g(a)-iminoester derivative capable of being stably present under ordinary conditions; and a method of synthesizing various $g(a)-aminoester derivatives from the $g(a)-iminoester derivative in high yield. The derivative is a polymer-i...
|
|
WO/2001/068071A2 |
A series of compounds of natural origin are described, as useful agents for the treatment of diseases characterised by abnormal angiogenesis. These compounds are: chrysanthone A having formula (I); chrysanthone B having formula (II); and...
|
|
WO/2001/066524A2 |
Intermediates useful for the synthesis of huperzine A represented by the structures (2) and (3), and methods for their synthesis, wherein: R?1¿ is lower alkyl, benzyl, or substituted benzyl; X is a suitable leaving group; Y is an electr...
|
